ClinicalTrials.gg
CompletedNCT05070312Updated Mar 25, 2022

Pharmacokinetics, Immunogenicity, Safety and Tolerability of MEDI3506 in Health Chinese Participants

A Phase 1 interventional study of MEDI3506 and Placebo in Healthy Volunteer, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-25.

Sponsored by AstraZeneca · Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is to evaluate the pharmacokinetics, immunogenicity, safety and tolerability of investigational drug MEDI3506 with single dose in Healthy Chinese participants.

Read the detailed description

A phase I, randomised, double-blind, placebo-controlled parallel-group study to evaluate the pharmacokinetics, immunogenicity, safety, and tolerability of single dose of MEDI3506 in healthy Chinese Participants

02

Conditions studied

  • Healthy Volunteer

Keywords

  • MEDI3506
  • Healthy Volunteers
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated, written prior to any study specific procedures.
  2. Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  3. Aged 18 to 45 years (inclusive, at the time of signing the ICF).
  4. Healthy, non smoking Chinese participants. Definition of non-smoker: non-smoker for at least the past 12 months with pack history ≤5 pack years.
  5. Able and willing to comply with the requirements of the protocol and complete the study until the end of the safety follow up period.
  6. Have a between 19 and 24 kg/m2 , inclusive.
  7. Male and female.
  8. Females of who are sexually active with a nonsterilized male partner must use a highly effective method of from enrolment throughout the study until their final follow-up visit. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method are not acceptable methods of contraception. Female condom and male condom should not be used together. All women of child bearing potential must have a negative serum pregnancy test result at Visit 1.

    • A highly effective method of contraception is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly. Highly effective birth control methods include: a vasectomised partner, Implanon®, bilateral tubal occlusion, intrauterine device/levonorgestrel intrauterine system, Depo-Provera™ injections, oral contraceptive, and Evra Patch™, Xulane™, or NuvaRing®.

    Females not of childbearing potential who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are . Women will be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatment prior to the planned date of randomization and follicle stimulating hormone (FSH) levels in the postmenopausal range.

  9. Nonsterilised males who are sexually active with a female partner of childbearing potential must use condom and spermicide from enrolment through the study period until their final follow up visit. Because male condom and spermicide is not a highly effective contraception method, female partners of a male study participants must also use a highly effective method of contraception as defined above throughout this period.

Exclusion criteria

Exclusion Criteria

  1. Any active medical or psychiatric condition or other reason which, in the opinion of the investigator, may compromise the safety of the participant in the study or interfere with evaluation of the product or reduce the participant's ability to participate in the study.
  2. Any abnormal findings on physical examination of the cardiovascular system including and vital signs at screening, and Day 1(pre-dose):

    a. Abnormal vital signs, after 10 minutes supine rest (confirmed by 1 controlled measurement), defined as any of the following: i. Fever greater than 37.5℃ ii. SBP \< 90 mmHg or ≥ 140 mmHg iii. DBP \< 50 mmHg or ≥ 90 mmHg iv. Pulse \< 45 or > 100 bpm b. Any clinically significant abnormalities in rhythm, conduction or morphology of the resting ECG, and any clinically significant abnormalities in the 12-lead ECG, as considered by the investigator that may interfere with the interpretation of changes, including abnormal ST-T wave morphology, or left ventricular hypertrophy.

  3. Any other clinically relevant abnormal findings on physical examination or laboratory testing including haematology, coagulation, clinical chemistry or urinalysis at screening or randomization, which in the opinion of the investigator may compromise the safety of the participant in the study or interfere with evaluation of the investigational product or reduce the participant's ability to participate in the study. Abnormal findings include, but are not limited to:

    1. Serum ' (ALT) or aspartate transaminase' (AST) > 2.0 × (ULN) or total (TBL) > 2 × ULN (unless due to Gilbert's disease) or evidence of chronic liver disease
    2. Total white blood cell count \< 4,000 × 106/L
    3. \< 1,500/mm3
    4. count \< 100,000/mm3
    5. \< 110 g/L
  4. History or a reason to believe that a participant has a history of drug or alcohol abuse within the past 2 years prior to screening.
  5. Positive drugs of abuse (DOA) including morphine, methamphetamine, ketamine, marijuana, methylenedioxymethamphetamin, and alcohol (unless can be explained by the participant's medications).
  6. Major surgery within 8 weeks prior to screening, or planned inpatient surgery or hospitalization during the study period.
  7. Donation of blood or blood products in excess of 400 mL within 3 months prior to screening and until the end of the follow-up period [Day 113].
  8. Participants who have a positive test for, or have been treated for , , Syphilis or . Regarding the hepatitis B testing (hepatitis B surface antigen [HBsAg], hepatitis B surface antibody [anti-HBs], hepatitis B core antibody [anti-HBc]), any of the following would exclude the participant from the study:

    1. Participants positive for HBsAg.
    2. Participants positive for anti-HBc. Participants with a history of hepatitis B vaccination without a history of Hepatitis B are permitted.
  9. Evidence of active or latent tuberculosis (TB):

    1. Positive diagnostic TB test during screening (defined as a positive interferon-gamma release assay [IGRA] test for TB at screening).
    2. Participants with an indeterminate IGRA should undergo repeat test and if still indeterminate may be enrolled only after treatment and subsequent negative IGRA.
  10. Evidence of active COVID-19 infection:

    1. Positive diagnostic COVID-19 PCR result Or
    2. Subject has severe COVID-19 infection as defined by positive COVID-19 PCR result and hospitalization or radiological evidence of pneumonia in the previous 6 months.
  11. Receiving any of the medications listed below:

    1. Any immunotherapy or therapy (within 1 year prior to randomization).
    2. Chronic use of medications.
    3. Investigational agents (within the last 3 months or at least 5 times the predicted half-life of the agent, whichever is greater).
    4. Marketed biologics, including omalizumab (within the last 3 months or at least 5 times the predicted half-life of the biologics, whichever is greater).
    5. Immunoglobulin or blood products (within 6 months prior or randomization).
    6. (until the end of the follow-up period [Day 113]).
  12. Treatment with broad spectrum antibiotic within 4 weeks prior to randomization (Day 1).
  13. Concurrent enrolment in another clinical study involving an investigational treatment.
  14. Received administration of an investigational drug or participated in a device trial within 3 months and 5.5 half-lives, prior to screening (Visit 1).
  15. History or current diagnosis of cancer, with the exception of cancer treated with apparent success with curative therapy (response duration of > 5 years).
  16. History of an underlying condition that predisposes the participant to infections (e.g., history of splenectomy, known primary or secondary immune deficiency syndromes).
  17. History of Inflammatory Bowel Disease or microscopic colitis.
  18. A known history of severe reaction to any medication including biologic agents and human gamma globulin therapy.
  19. History of bone marrow transplant.
  20. History of a viral, bacterial, or fungal significant infection (including unexplained diarrhea) within 4 weeks (28 days) prior to randomization (Day 1) or clinical suspicion of infection at the time of dosing.
  21. History of herpes zoster within 3 months prior to randomization (Day 1).
  22. Participants with recent (within 12 months) clinical history of infective hepatitis or unexplained jaundice.
  23. Participant is a participating investigator, sub-investigator, study coordinator, or employee of the participating site, or is a first-degree relative of the aforementioned.
  24. Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures and/or follow-up or any conditions that, in the opinion of the investigator, may render the patient unable to complete the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    MEDI3506 dose 1

    MEDI3506 dose1

    Biological: MEDI3506

  • Experimental
    MEDI3506 dose 2

    MEDI3506 dose 2

    Biological: MEDI3506

  • Placebo comparator
    Placebo

    Placebo 2 mL and 4 mL

    Drug: Placebo

Interventions

  • BiologicalMEDI3506

    MEDI3506

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration (Cmax)

    To assess the maximum plasma concentration of MEDI3506 after single subcutaneous administrations in healthy Chinese participants.

    Time frame: Day 1 to Day 113

  2. Area under the serum concentration time curve to the infinite (AUC0-inf)

    To assess the area under the serum concentration time curve from pre-dose until infinite after single Subcutaneous administration of MEDI3506 in healthy Chinese participants

    Time frame: Day 1 to Day 113

  3. Area under the serum concentration time curve to the last observation(AUC0-t)

    To assess the area under the serum concentration time curve from pre-dose until the last observation quantified after single Subcutaneous administration of MEDI3506 in healthy Chinese participants

    Time frame: Day 1 to Day 113

  4. Terminal Elimination half-life (t1/2)

    To assess the terminal elimination half-life after single Subcutaneous administration of MEDI3506 in healthy Chinese participants

    Time frame: Day 1 to Day 113

  5. Apparent total body Clearance (CL/F)

    To evaluate the apparent MEDI3506 total body clearance from serum after single subcutaneous administration of MEDI3506 in healthy Chinese participants

    Time frame: Day 1 to Day 113

  6. Apparent volume of distribution based on terminal phase (Vz/F)

    To assess the apparent volume of distribution of MEDI3506 after single subcutaneous administration of MEDI3506 in healthy Chinese participants

    Time frame: Day 1 to Day 113

  7. Time to reach maximum observed concentration (tmax)

    To assess the MEDI3506 time to reach peak serum concentration after single subcutaneous administration of MEDI3506 in healthy Chinese participants.

    Time frame: Day 1 to Day 113

Secondary outcomes

  1. Immunogenicity determined by prevalence of antidrug antibodies (ADA)

    Immunogenicity prevalence measured as number of participants with ADA positive at baseline and/or post-baseline

    Time frame: Day 1 (-30~0 min before IP administration), and on Day 8, Day 29, Day 57, Day 85 and Day 113

  2. Immunogenicity determined by incidence of ADA

    Immunogenicity incidence measured as number of participants with positive treatment emergent ADA

    Time frame: Day 1 (-30~0 min before IP administration), and on Day 8, Day 29, Day 57, Day 85 and Day 113

Other outcomes

  1. Incidence of treatment-emergent AE

    The number and percentage of participants with treatment-emergent AE will be displayed by MedDRA SOC and PT

    Time frame: Day 1 to Day 113

  2. Incidence of treatment-emergent SAE

    The number and percentage of participants with treatment-emergent SAE will be displayed by MedDRA SOC and PT

    Time frame: Day 1 to Day 113

  3. Safety as determined by evaluation of blood pressure in mmHg

    Measurement of blood pressure (systolic and diastolic in mmHg)

    Time frame: Day 1 to Day 113

  4. Safety as determined by evaluation of Pulse rate in beats per minute

    Measurement of Pulse rate in beats per minute

    Time frame: Day 1 to Day 113

  5. Safety as determined by evaluation of Respiratory rate in beats per minute

    Measurement of Respiratory rate in beats per minute

    Time frame: Day 1 to Day 113

  6. Safety as determined by evaluation of body temperature in degree Celsius

    Measurement of body temperature in degree Celsius

    Time frame: Day 1 to Day 113

  7. Safety as determined by analysis of 12-lead ECG: heart rate (unit: beats per minute)

    The ECG heart rate will be summarized by absolute value at each visit by treatment group, together with the corresponding changes from baseline.

    Time frame: Day 1 to Day 113

  8. Safety as determined by analysis of 12-lead ECG QT interval (units: milliseconds)

    The ECG variable will be summarized by absolute value at each visit by treatment group, together with the corresponding changes from baseline.

    Time frame: Day 1 to Day 113

  9. Safety as determined by analysis of 12-lead ECG QTcF interval (units: milliseconds)

    The ECG variable will be summarized by absolute value at each visit by treatment group, together with the corresponding changes from baseline.

    Time frame: Day 1 to Day 113

  10. Safety as determined by abnormality in hematology

    Measurement of red blood cell count, Leukocyte count, Leukocyte differential count, haemoglobin, platelets, PT, aPTT, INR.

    Time frame: Day 1 to Day 113

  11. Safety as determined by abnormality in clinical chemistry

    Measurement of kidney function (blood urea nitrogen creatinine, Uric acid), liver function (ALP, ALT, AST, albumin, total bilirubin), total protein, potassium, calcium total, sodium, creatine kinase, glucose.

    Time frame: Day 1 to Day 113

  12. Safety as determined by abnormality in urinalysis

    Measurement of glucose, ketones, leukocytes, erythrocytes, blood and protein.

    Time frame: Day 1 to Day 113

07

Study locations

1 site
  • Research Site
    Suzhou, 215006, China
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessor) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Feb 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2021
First posted
Oct 7, 2021
StartActual
Aug 23, 2021
Primary completionActual
Feb 7, 2022
CompletionActual
Feb 7, 2022
Last update
Mar 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05070312
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 7, 2021
Start date
Aug 23, 2021
Primary completion
Feb 7, 2022
Completion
Feb 7, 2022
Last update
Mar 25, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tozorakimab

Start the discussion